Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients With Severe Sickle Cell Disease

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients With Severe Sickle Cell Disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BEAM 101 (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BEACON
  • Sponsors Beam Therapeutics

    • Most Recent Events

    • 08 Aug 2023 According to the Beam Therapeutics media release, the company continues to anticipate reporting initial data on multiple patients from the BEACON trial in 2024.
    • 08 Aug 2023 According to the Beam Therapeutics media release, the company has continued to consent additional patients and anticipates that currently consented patients are sufficient to both fill the sentinel cohort (n=3) and to initiate the expansion cohort. The company will continue adding additional patients to the BEACON trial through the end of year and beyond, with a total target of 45 treated patients.
    • 08 Aug 2023 According to the Beam Therapeutics media release, the first patient having been consented and dosing expected this quarter.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top